CAR T Cell Therapy

Promising technologies for lymphoma, leukemia & multiple myeloma treatment.

Chimeric Antigen Receptor T-cell therapy is also known as CAR T cell therapy, it is a recently developed cancer treatment that offers hope to people with lymphoma, leukemia and multiple myeloma that are hard to treat. lt has the potential to cure cancer and was approved by the FDA in the US in 2017.

Why China?

China’s cautious approach to approving CAR T cell therapy reflects its commitment to ensuring patient safety and effectively managing potential side effects of this innovative treatment. Despite being among the first countries to offer CAR T cell therapies, the National Medical Products Administration (NMPA) took deliberate steps to evaluate and regulate the therapy before granting approval. By prioritizing thorough assessment and oversight, the NMPA aimed to mitigate risks and optimize patient outcomes. This careful consideration underscores China’s dedication to advancing medical innovation while upholding rigorous standards for patient care and safety. As a result, thousands of patients have benefited from CAR T cell therapy in Chinese hospitals, with confidence in the treatment’s efficacy and safety.

Traveling to China for CAR T cell therapy offers several compelling reasons:

  1. Reliable Technology with Exceptional Outcomes: China has established itself as a leader in CAR T cell therapy research and development, with a robust scientific foundation and cutting-edge technologies. Clinical trials in China have demonstrated outcomes comparable to CAR T therapies worldwide, indicating the reliability and effectiveness of the treatments available.

  2. Global Leadership in CAR T Cell Therapy Research: With over 500 clinical trials underway in more than 300 hospitals across the country, China is at the forefront of CAR T cell therapy research and practice. This extensive network of clinical trials reflects China’s commitment to advancing the field and exploring innovative treatment options for patients.

  3. Patient-Friendly Pricing Strategies: CAR T cell therapies in China are priced with patient-friendly strategies, making them more accessible to patients in need. By prioritizing affordability and accessibility, China ensures that CAR T cell therapy is a viable treatment option for a broader range of patients, both domestically and internationally.

The research and development of CAR T cell therapy in China is rapid, and the doctors are experienced in handling CAR T cell therapy. China has surpassed the US and became the first in terms of the number of clinical trials, there are over 500 trials taking place at present in the country, the overall cure rate of CAR T cell therapy in China is among the best in the world.

Apart from the doctors’ expertise, China offers medical care at an affordable cost, including CAR T cell therapy. CAR T cell therapy is a pricey treatment, it costs USD 450,000 in the US, however, it costs less than half in China, and most importantly, there is no deduction in quality.

Overall, the combination of reliable technology, leadership in research, and patient-friendly pricing makes China an attractive destination for individuals seeking CAR T cell therapy.

Here, we will go through the process you will undergo if you are potentially qualified for the treatment. If you are interested in traveling to China and receiving CAR T cell therapy feel free to contact us using the contact form on the right, we will contact you shortly with detailed information, and will help you go through the process of traveling over to China.

Why going to China for cancer treatment?

Fact of CAR T Cell Therapy in China

Approved Therapies
0 %
Remission Rate
0 +
Patients Treated
0 +
Clinical Studies

Potential Benefits

CAR T cell therapy represents a groundbreaking approach to cancer treatment, offering highly targeted and potent anti-cancer activity with the potential for long-term remission, particularly in refractory or relapsed hematologic malignancies like lymphoma, leukemia and multiple myeloma. The potential benefits of CAR T cell therapy including the following:

  • Highly Targeted Treatment: CAR T cell therapy is designed to target specific cancer cells carrying a particular antigen. This specificity can minimize damage to healthy cells, reducing side effects compared to traditional chemotherapy or radiation therapy.

  • Potent Anti-Cancer Activity: Engineered CAR T cells are highly effective at recognizing and destroying cancer cells. They can persist in the body for long periods, providing ongoing surveillance and potentially preventing cancer recurrence.

  • Potential for Long-Term Remission: CAR T cell therapy has demonstrated durable responses in some patients, leading to long-term remission or even cure, particularly in certain types of leukemia and lymphoma.

  • Treatment for Refractory or Relapsed Cancers: CAR T cell therapy offers a treatment option for patients whose cancer has not responded to other therapies or has relapsed after initial treatment, providing hope for individuals who may have otherwise limited treatment options.

  • Personalized Medicine Approach: CAR T cell therapy can be tailored to each patient based on their specific cancer type and antigen expression, representing a personalized medicine approach that may improve treatment outcomes.

  • Single Treatment Administration: In many cases, CAR T cell therapy involves a single infusion of engineered T cells, which can provide a prolonged therapeutic effect without the need for frequent treatments or ongoing chemotherapy cycles.

  • Potential for Broad Applicability: While CAR T cell therapy has initially been successful in treating certain blood cancers, ongoing research is exploring its effectiveness in solid tumors and other types of cancer, potentially broadening its applicability in the future.

  • Continued Advancements: Research and development in CAR T cell therapy are ongoing, leading to improvements in safety, efficacy, and scalability. This ongoing innovation may further enhance the benefits of this treatment modality in the years to come.

Despite these potential benefits, it’s essential to acknowledge that CAR T cell therapy also carries risks and limitations, including immune-related toxicities, cytokine release syndrome, neurotoxicity, and the potential for long-term side effects. Additionally, access to CAR T cell therapy may be limited due to factors such as cost, infrastructure requirements, and patient eligibility criteria.

Effectiveness of CAR T Cell Therapy

CAR T cell therapy has shown promising outcomes in the treatment of lymphoma, leukemia and multiple myeloma, many patients who had previously relapsed lymphoma experienced positive outcomes and no evidence of recurrence of cancer.

CAR T cell therapies developed in China have showcased remarkable efficacy in treating these conditions with the following outcomes:

  • R/R LBCL: ORR 100%
  • FL: ORR 92.58%
  • R/R MM: ORR 99%
  • R/R ALL: 64.10%

Development of CAR T-Cell therapy in China

According to data published on, among 25 countries that have initiated clinical trials with CAR T-cells, China is the country with the majority of CAR T cell clinical trials registered as of March 2022, with 460 studies, followed by the USA presented 286 studies, while the Uk had 14, and Germany had 9.

Furthermore, CD19 is the most frequently examined target in these registered clinical studies. CD20, CD22, and BCMA are also common CAR T cell therapy targets for hematologic malignancies. Research of CAR T-cell therapy in the treatment of solid cancers are undergo in a number of institutes.

Treatment Process

Unlike other treatments such as chemotherapy or radiotherapy, CAR T-cell therapy is a biological and personalized live medicine manufactured from patient’s own white blood cells, its criteria and requirement must be followed in order for a safe and effective treatment. Here are a few steps a patient will go through if he wishes to have CAR T cell therapy.

1. Evaluation

A full assessment of patient's condition is performedbefore CAR T-cell therapy.

2.WBC Collection

Collecting patient's own white blood cells formanufacture of CAR T-cells.

3.T Cell Modification & Growth

T cells are engineered and multiplied in the lab to recognize cancer cells in patient's body.


Chemotherapy may be required prior to CAR T cell therapy for better effort.

5.Infusion of CAR T Cells

Infusing CAR T cells back to patient's body, and fightagainst cancer.


A 2-3 month of recovery period is needed after treatment.

Side Effects

The side effects of CAR T-cell therapy usually resolve on their own or they can be managed with medications.The common side effects ofCAR T-cell therapy include.

Cytokine release syndrome

In some cases, patients may develop flu-like symptoms such as fever, chills, headache, nausea, vomiting, loose stools, and muscle or joint pains. it may also cause low blood pressure, dificulty in breathing, and a fast heart rate. these side effects are due to the release of cytokines by the immune cells during CAR T cell therapy. These symptoms are usualy mild, but can be serious and life threatening in some patients.

Neurological events

Neurological events can occur and can be serious in some patients. such events include encephalopathy (brain iniury and malfunction confusion, difficulty speaking, agitation, seizures, drowsiness, altered state of consciousness and loss of balance.

Neutropaenia and Anaemid

Some patients may develop neutropenia or low white cell count. similarly,anaemia or low red blood cell count may also occur due to this therapy.